In 2002, Senator Clinton worked with Republican Mike DeWine (remember when that was possible?) to pass the Pediatric Research Equity Act. This law ensured that pharmaceuticals aimed at children actually had proper pediatric research. As a result of this law, 54 drugs were relabeled so that doctors and patients were aware of potential serious side effects in children. For example:

Fluoxetine (Prozac) underwent major labeling changes after a 19-week clinical pediatric trial of its use for major depressive disorder in patients aged 8 to 17 and obsessive-compulsive disorder in patients aged 7 to 17 found that those taking the drug experienced more limited growth than those not taking it. The label now warns physicians to monitor the height and weight of pediatric patients treated with fluoxetine.

This kind of legislation doesn’t make a big splash in the news, but it makes a big difference in the lives of the children using these medications. It also highlights Hillary Clinton’s ability to work with many different people to achieve her goals.

Daily Kos: Hillary Clinton’s Accomplishments – Pediatric Research Equity Act

Senator Clinton’s Floor Statement on PREA

NIH: Impact of Pediatric Drug Legislation